Literature DB >> 15147363

Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes.

R Chauhan1, R Handa, T P Das, U Pati.   

Abstract

The aim of this study was to determine the expression levels of p53 and TATA binding protein (TBP) and the presence of autoantibodies to these antigens in Asian Indian patients with systemic sclerosis (SSc), overlap syndromes (OS) and systemic lupus erythematosus (SLE). Fifty patients with SSc, 20 with OS, including mixed connective tissue diseases (MCTD), 20 with SLE, 10 disease controls (DC) and 25 controls (C) were studied. The over-expression of p53 and TBP antigen was determined quantitatively by sandwich enzyme-linked immunosorbent assay (ELISA), varies between four- and sevenfold higher in patients with SSc, OS and SLE, in comparison to DC and C. The expressed protein antigens were not present as free antigens but as immune-complexes. Autoantibodies to p53 were detected by ELISA in 78% subjects with SSc, 100% with OS and 80% with SLE. Autoantibodies to TBP were observed in 28% patients with SSc, 25% with OS and 15% with SLE. In comparison to healthy controls, the titre of antibodies to p53 was significantly higher in patients with SSc (P = 0.00001) than the patients with OS (P = 0.00279) and SLE (P = 0.00289), whereas the titre of antibodies to TBP was higher in patients with OS (P = 0.00185) than the SLE (P = 0.00673) and the SSc (P = 0.00986) patients. Autoantibodies to p53 and TBP were detected in all these patients and the levels of these two autoantibodies showed weak negative correlation with each other. We propose that the over-expression of these antigens might be due to hyperactive regulatory regions in the p53 and TBP gene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147363      PMCID: PMC1809039          DOI: 10.1111/j.1365-2249.2004.02463.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Absence of p53 mutation in Japanese patients with rheumatoid arthritis: comment on the article by Han et al.

Authors:  H Kitasato; R Okamoto; S Kawai
Journal:  Arthritis Rheum       Date:  2000-02

Review 2.  Ribonucleoprotein complexes as autoantigens.

Authors:  W J van Venrooij; G J Pruijn
Journal:  Curr Opin Immunol       Date:  1995-12       Impact factor: 7.486

3.  Autoantibodies to p53 in sera of patients with autoimmune thyroid disease.

Authors:  C L Fenton; A Patel; R M Tuttle; G L Francis
Journal:  Ann Clin Lab Sci       Date:  2000-04       Impact factor: 1.256

4.  Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium.

Authors:  M Inazuka; T Tahira; T Horiuchi; S Harashima; T Sawabe; M Kondo; H Miyahara; K Hayashi
Journal:  Rheumatology (Oxford)       Date:  2000-03       Impact factor: 7.580

5.  Serum anti-p53 autoantibodies in patients with type 1 diabetes.

Authors:  E Di Cesare; M Previti; F Lombardo; A Di Benedetto; N Mazzù; G Romano; F De Luca; A Lasco; D Cucinotta
Journal:  Ann Clin Lab Sci       Date:  2001-07       Impact factor: 1.256

6.  [Expression of p53 in the skin in systemic sclerosis. Immunohistochemical study of 8 cases].

Authors:  A Pignone; A Calzolari; M M Cerinic; C Scaletti; L Messerini; A Lombardi; S Generini; E Giannelli; A Carossino; G Baroni
Journal:  Pathologica       Date:  1994-08

Review 7.  Mechanisms of autoantibody diversification to SLE-related autoantigens.

Authors:  Umesh S Deshmukh; Felicia Gaskin; Janet E Lewis; Carol C Kannapell; Shu Man Fu
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

8.  Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III.

Authors:  M Hirakata; Y Okano; U Pati; A Suwa; T A Medsger; J A Hardin; J Craft
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 9.  Autoantibodies in scleroderma and tightskin mice.

Authors:  C Bona; N Rothfield
Journal:  Curr Opin Immunol       Date:  1994-12       Impact factor: 7.486

10.  Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements.

Authors:  C Bensimon; P Chastagner; M Zouali
Journal:  EMBO J       Date:  1994-07-01       Impact factor: 11.598

View more
  10 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

2.  Association study between the TP53 Rs1042522G/C polymorphism and susceptibility to systemic lupus erythematosus in a Chinese Han population.

Authors:  Jie Yang; Ji-Min Zhu; Song Wu; Jing Li; Ming-Rui Wang; Ting-Ting Wang; Yu-Wei Lu
Journal:  Rheumatol Int       Date:  2017-02-09       Impact factor: 2.631

3.  Confirmation of five novel susceptibility loci for systemic lupus erythematosus (SLE) and integrated network analysis of 82 SLE susceptibility loci.

Authors:  Julio E Molineros; Wanling Yang; Xu-Jie Zhou; Celi Sun; Yukinori Okada; Huoru Zhang; Kek Heng Chua; Yu-Lung Lau; Yuta Kochi; Akari Suzuki; Kazuhiko Yamamoto; Jianyang Ma; So-Young Bang; Hye-Soon Lee; Kwangwoo Kim; Sang-Cheol Bae; Hong Zhang; Nan Shen; Loren L Looger; Swapan K Nath
Journal:  Hum Mol Genet       Date:  2017-03-15       Impact factor: 6.150

Review 4.  Perception of self: distinguishing autoimmunity from autoinflammation.

Authors:  Tessa S van Kempen; Mark H Wenink; Emmerik F A Leijten; Timothy R D J Radstake; Marianne Boes
Journal:  Nat Rev Rheumatol       Date:  2015-05-12       Impact factor: 20.543

Review 5.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

6.  Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.

Authors:  Laura C Hurley; Nancy K Levin; Madhumita Chatterjee; Jasmine Coles; Shlomo Muszkat; Zachary Howarth; Gregory Dyson; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2020       Impact factor: 4.388

Review 7.  The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target.

Authors:  Alessandra Fierabracci; Marsha Pellegrino
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

Review 8.  Dysregulation of Cell Death and Its Epigenetic Mechanisms in Systemic Lupus Erythematosus.

Authors:  Haijing Wu; Siqi Fu; Ming Zhao; Liwei Lu; Qianjin Lu
Journal:  Molecules       Date:  2016-12-27       Impact factor: 4.411

9.  Activation of innate immunity by mitochondrial dsRNA in mouse cells lacking p53 protein.

Authors:  Dagmara M Wiatrek; Maria E Candela; Jiří Sedmík; Jan Oppelt; Liam P Keegan; Mary A O'Connell
Journal:  RNA       Date:  2019-03-20       Impact factor: 4.942

10.  Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients.

Authors:  Marsha Pellegrino; Gianandrea Traversi; Andrea Arena; Marco Cappa; M Manuela Rosado; Marco Andreani; Domenico V Delfino; Fabiola Moretti; Alessandra Fierabracci
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.